An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab，Mendeley Supplements

1. Supplemental Materials including: Supplementary Figure 1: Flow diagram of study; Supplementary Figure 2: Numbers of AD patients achieving EASI 25/50/75 at week 2, 4, 8 and week 12. Supplementary Figure 3: Numbers of AD patients achieving SCORAD 25/50/75 at week 2, 4, 8 and week 12. Supplementary Figure 4: Clinical photographs and the EASI score of two typical patients during the follow-up. Supplemental Table 1: Demographic and clinical characteristics of 16 patients. Supplemental Table 2: Laboratory parameters before and during abrocitinib treatment. 2. Supplemental Methods